bioAffinity Technologies Restores Nasdaq Compliance, Strengthening Path Toward Long-Term Growth
bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company dedicated to advancing early-stage cancer diagnostics, announced that it has successfully regained compliance with all Nasdaq Capital Market continued listing requirements. This milestone ensures that the company’s common stock and warrants will continue trading under the symbols BIAF and BIAFW, respectively.
The confirmation follows an official notice from The Nasdaq Stock Market LLC, dated October 14, 2025, informing bioAffinity Technologies that it now meets the criteria outlined in Nasdaq Listing Rule 5550(a)(2) and Nasdaq Listing Rule 5550(b)(1). These rules mandate that a company’s stock maintain a minimum closing bid price of $1.00 per share and a minimum of $2.5 million in stockholders’ equity, respectively.
A Strategic Milestone for Continued Growth
Regaining compliance marks a pivotal moment for bioAffinity Technologies as it continues to expand its presence in the field of noninvasive cancer diagnostics. The company’s flagship product, CyPath® Lung, is a commercially available test designed for the early detection of lung cancer. This diagnostic tool is positioned to play a transformative role in improving survival rates by identifying lung cancer in its earliest and most treatable stages.
Maria Zannes, President and Chief Executive Officer of bioAffinity Technologies, expressed optimism about the company’s forward trajectory following the Nasdaq decision.
We are pleased to have regained full compliance with Nasdaq’s listing standards,” said Zannes. “Maintaining our Nasdaq listing allows us to focus on advancing our CyPath® Lung test for lung cancer and our broader pipeline of noninvasive diagnostics while also building shareholder value for the long term.”
Zannes further emphasized that maintaining Nasdaq compliance provides greater stability and credibility with investors, partners, and stakeholders, reinforcing the company’s strategic foundation as it pursues its mission to detect cancer early through accessible, accurate diagnostics.
Strengthening Financial and Operational Position
The Nasdaq compliance notice reflects not only bioAffinity’s ability to meet equity and valuation benchmarks but also the company’s commitment to fiscal discipline and strategic growth. The company’s compliance with Listing Rule 5550(a)(2) (Minimum Bid Price Rule) signifies that bioAffinity has successfully maintained its share price above the required $1.00 threshold for the prescribed period. Similarly, compliance with Listing Rule 5550(b)(1) (Equity Rule) indicates that the company’s financial position meets the Nasdaq Capital Market’s standards for ongoing listing.
While achieving compliance restores full trading eligibility, Nasdaq has also informed bioAffinity that it will remain under a Mandatory Panel Monitor for a period of one year. During this monitoring period, the company must continue to meet the Equity Rule’s requirements to remain in good standing. If bioAffinity were to fall below compliance within that timeframe, it would not be granted an automatic extension but would have the opportunity to request a hearing before the Nasdaq Listing Qualifications Hearing Panel prior to any delisting action.
This additional oversight underscores Nasdaq’s confidence in bioAffinity’s operational recovery while ensuring continued adherence to market standards.
Commitment to Innovation in Early Cancer Detection
bioAffinity Technologies has built its scientific platform around developing noninvasive diagnostic tests that enable early cancer detection through cellular analysis. Its CyPath® Lung test—currently available for physicians and patients—uses a proprietary combination of flow cytometry and fluorescence-based technology to distinguish cancerous from non-cancerous cells found in sputum samples.
By identifying lung cancer in its initial stages, CyPath® Lung aims to fill a critical gap in preventive oncology. Lung cancer remains one of the world’s leading causes of cancer-related mortality, in part because it is often diagnosed too late. Early detection not only increases survival rates but also improves treatment outcomes and reduces healthcare costs.
Beyond CyPath® Lung, the company continues to invest in a pipeline of diagnostic tests targeting other cancers, applying the same scientific principles of cellular microenvironment analysis to multiple disease areas. These innovations align with bioAffinity’s vision of creating accessible, accurate, and cost-effective solutions for early disease detection and management.
Looking Ahead: Investor Confidence and Strategic Focus
Maintaining a Nasdaq listing is more than a technical requirement—it is a signal of stability and credibility for investors and partners. For bioAffinity Technologies, this development reinforces confidence among shareholders and enhances its ability to attract future capital, partnerships, and strategic collaborations.
The company’s leadership views this compliance milestone as an enabler for its next phase of growth, particularly as it works to expand the commercial reach of CyPath® Lung in the U.S. market. BioAffinity also continues to explore research collaborations and distribution partnerships that could extend the test’s accessibility globally.
Zannes reiterated that the company’s Nasdaq standing strengthens its long-term objectives:
Being in full compliance with Nasdaq’s listing standards represents our continued progress in building a strong and sustainable company. We are committed to innovation in early cancer detection, fiscal responsibility, and creating value for our shareholders.”
bioAffinity Technologies’ restoration of Nasdaq compliance represents both a financial and strategic victory. It demonstrates resilience in maintaining its market presence and underscores the company’s commitment to operational excellence and scientific innovation.
With the compliance issue resolved, bioAffinity Technologies is now well-positioned to advance its mission of transforming cancer diagnostics—bringing life-saving tools like CyPath® Lung to a broader population and expanding its noninvasive diagnostic platform to address multiple cancers in the future.
